EDAP TMS Reports Continued Progress in European Marketing.
LYON, France, July 12 /PRNewswire-FirstCall/ -- EDAP EDAP Eating Disorders Awareness and Prevention
EDAP Extended Data Availability and Protection (fault tolerant disk technology)
EDAP Emergency Department Approved for Pediatrics
EDAP Energy Descent Action Plan TMS TMS Transcranial Magnetic Stimulation (alternative medicine for depression)
TMS Test Match Special (sports - cricket)
TMS Texas Motor Speedway
TMS Transportation Management System
TMS Toyota Motor Sales S.A. is pleased to report continued growing interest in minimally invasive prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. treatment utilizing the company's market leading Ablatherm(R)-HIFU platform at two conferences held in Europe.
EDAP participated in the 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases, co-sponsored by the International Union Against Cancer, in Paris, June 24-27, 2005. The conference is the most recognized worldwide event for discussing prostate cancer and prostate disease while assessing new trends in the fast developing area of research against cancer.
Pr. Pierre Conort, from Hopital La Pitie Salpetriere in Paris, presented an overview of features unique to Ablatherm(R)-HIFU including safety, quality ultrasound imaging, long-term clinical data, reduced occurrence of side effects Side effects
Effects of a proposed project on other parts of the firm. and repeatability of treatment while discussing key factors differentiating Ablatherm-HIFU from other technology. Pr. Conort has used Ablatherm-HIFU to successfully treat localized prostate cancer for more than four years.
Pr. Pierre Conort commented: "Ablatherm-HIFU is the only proven technology based on long-term clinical data. It has been used on a routine basis, for well-selected patients whose treatment requires its unique benefits, since 2001. Ablatherm-HIFU treatment has a multi-year body of clinical data demonstrating very low side effects and high tolerance in patients. Additionally, it is a valuable option for patients who failed a prior radiotherapy procedure and do not have other alternatives for their prostate cancer treatment."
The Ablatherm-HIFU unit recently introduced an industry leading enhanced 3-D integrated imaging system allowing the urologist to efficiently visualize the patient prostate while focusing the high intensity ultrasound. Using the optimized parameters developed based on years of clinical practice, urologists can safely and effectively treat localized prostate cancer. The continuous refinement of these parameters has steadily reduced the incidence of typical side effects reported in other traditional treatments while offering the patient an easier recovery as compared to surgical removal of the diseased prostate.
Dr. John Warner, from the Don Mills Surgical Unit in Toronto, Canada, presented a video session on Ablatherm-HIFU detailing an Ablatherm treatment procedure and discussing the various steps. Dr. Warner also discussed how the newly integrated imaging system enhances detail in imaging and control for the physician during treatment. He concluded by presenting Ablatherm-HIFU five-year results and successful outcomes for radiotherapy failure patients. This presentation was highly attended and urologists demonstrated great interest in inquiring further about this technique and its unique advantages.
EDAP also presented at the B.A.U.S. (British Association of Urology Surgeons) meeting held in Glasgow, Scotland, from June 27 to July 1, 2005. Ablatherm-HIFU received approval from the National Institute for Clinical Excellence (NICE) in early 2005, a key recommendation for acceptance within the U.K. urology community as well as future insurance reimbursement of the procedure. British Urologists showed great interest specifically in Ablatherm-HIFU technology as an additional treatment option for patients who are ill equipped to handle the rigors of surgery or who failed previous radiation treatment. Urologists visited with representatives from both EDAP and its U.K. distributor Sigmacon to discuss Ablatherm-HIFU treatment of prostate cancer as well as take part in informational discussions about the technology and its results.
"We are very pleased with the outcomes from these two conference events in furthering the demand for and recognition of Ablatherm-HIFU as the leading minimally invasive therapeutic option for the treatment of localized prostate cancer in Europe," said Hugues de Bantel, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of EDAP. "EDAP will continue to build on its strength in clinical results as we successfully treat an ever increasing number of patients seeking an alternative to traditional therapies for localized prostate cancer."
Commenting on the company's continued growth in the U.K. market, de Bantel stated, "We are very pleased to begin active work in the U.K. to advance the knowledge of this very attractive treatment option within the urology community. The pipeline is building for the U.K. market as we continue in our efforts to gain reimbursement approval."
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound HIFU (high intensity focused ultrasound) (sometimes FUS or HIFUS) is a highly precise medical procedure using high-intensity focused ultrasound to heat and destroy pathogenic tissue rapidly. (HIFU HIFU High-intensity focused ultrasound Surgery A method that focuses ultrasound to heat/ablate target tissue without injuring surrounding structures. See Sonablate 200™. ) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy Lithotripsy Definition
Lithotripsy is the use of high-energy shock waves to fragment and disintegrate kidney stones. The shock wave, created by using a high-voltage spark or an electromagnetic impulse, is focused on the stone. (ESWL ESWL (Extracorporeal shock wave lithotripsy)
The use of focused shock waves, generated outside the body, to fragment kidney stones.
Mentioned in: Lithotripsy ).
For more information on the Company, contact the Investor Relations Investor relations
The process by which the corporation communicates with its investors. Dept by phone at +33 (0) 4 78 26 40 46 or see the Company's Web site at: http://www.edap-tms.com/ .
This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.
CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe Chauveau Blandine Confort +33 4 78 26 40 46 Halliburton Investor Relations Matt Kreps - Geralyn DeBusk 972 458 8000
CONTACT: Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps, or Geralyn DeBusk, both of Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A.
Web site: http://www.edap-tms.com/